TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06112678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(6)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(6)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO
Study: NCT05029193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Langerian mindfulness
Description: A 3-week Langerian mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Langerian mindfulness
Description: A 3-week Langerian mindfulness intervention will be offered entirely online. The purpose of the intervention is: 1) to increase participants' mindfulness, and 2) to encourage participants to change their beliefs about the disability associated with stroke to improve their psychological state. Mindfulness refers to the act of being aware: aware of thoughts, aware of emotions, aware of physical sensations, aware of others. The intervention consists of educational texts, daily exercises, audio recordings and videos. Five different topics related to mindfulness will be introduced throughout the intervention.
Study: NCT05721690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UED-A Videolaryngoscopy
Description: Tracheal Intubation with UED-A videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope Videolaryngoscopy
Description: Tracheal Intubation with Glidescope Titanium videolaryngoscope
Study: NCT06271759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fragrance inhalation
Description: Inhalation of fragranced essential oils

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fragrance inhalation
Description: Inhalation of fragranced essential oils

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fragrance inhalation
Description: Inhalation of fragranced essential oils

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fragrance inhalation
Description: Inhalation of fragranced essential oils
Study: NCT04960397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Physiological saline, i.e., 0.9% sodium chloride.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Physiological saline, i.e., 0.9% sodium chloride.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Physiological saline, i.e., 0.9% sodium chloride.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Physiological saline, i.e., 0.9% sodium chloride.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sing2016 M2SR H3N2
Description: Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sing2016 M2SR H3N2
Description: Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sing2016 M2SR H3N2
Description: Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sing2016 M2SR H3N2
Description: Novel intranasal live attenuated influenza vaccine with a defective M2 gene which renders the virus unable to replicate and generate progeny in animals and in humans, making its infectivity self-limiting. It induces both a mucosal and cell-mediated immune response and is administered intranasally. Supplied by Flugen Inc.
Study: NCT05994261

Intervention type: DEVICE
Group type: OTHER
Intervention: Cereset Research
Description: The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cereset Research
Description: The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study: NCT05437042

Intervention type: OTHER
Intervention: Medial calcaneal wedge
Description: Immediate effect of medial calcaneal wedge for static balance and weight distribution
Study: NCT05976113

Intervention type: OTHER
Intervention: Observation only
Description: Just obsrevation following standard of care (including surgery, chemotherapy and radiation when appropriate)
Study: NCT04912141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conestat alfa or placebo
Description: Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conestat alfa or placebo
Description: Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conestat alfa or placebo
Description: Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conestat alfa or placebo
Description: Conestat alfa will be dosed by body weight at 50 U/kg (maximum 4200 U) or 100 U/kg (maximum 8400 U).~Placebo will consist of normal saline (NaCl 0.9%). The interventions will be given to the patients by IV-line.
Study: NCT06013332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBF PLLA microsphere (injectable poly-L-lactic acid)
Description: Poly-L-lactic acid (PLLA) is a collagen stimulator, helps restore the deep, underlying structure of the skin to diminish facial wrinkles. PLLA microparticles are absorbable for human body, and it works with human body within the deep dermis to help revitalize collagen production and help restore human skin's inner structure and volume. PLLA can rebuilt collagen strands begin gradually helping to restore facial volume and the look of fullness to wrinkles and folds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBF PLLA microsphere (injectable poly-L-lactic acid)
Description: Poly-L-lactic acid (PLLA) is a collagen stimulator, helps restore the deep, underlying structure of the skin to diminish facial wrinkles. PLLA microparticles are absorbable for human body, and it works with human body within the deep dermis to help revitalize collagen production and help restore human skin's inner structure and volume. PLLA can rebuilt collagen strands begin gradually helping to restore facial volume and the look of fullness to wrinkles and folds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra®
Description: Sculptra®

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra®
Description: Sculptra®
Study: NCT06195124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGL-193（low-dose）
Description: Each side of the putamen received 150 μL of RGL-193, with a unilateral dose of 1.5×10\^11 VG and a bilateral dose of 3.0×10\^11 VG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGL-193（high-dose）
Description: Each side of the putamen received 200 μL of RGL-193, with a unilateral dose of 5.0×10\^11 VG and a bilateral dose of 1.0×10\^12 VG.
Study: NCT05364619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qingre Huashi Granules combined the modified dual therapy
Description: Qingre Huashi Granules combined the modified dual therapy for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth containing quadruple therapy
Description: Bismuth containing quadruple therapy for 14 days
Study: NCT06257901

Intervention type: OTHER
Intervention: Interviews/Focus groups/Participatory workshops
Description: Qualitative study (no intervention delivered)

Intervention type: OTHER
Intervention: Interviews/Focus groups/Participatory workshops
Description: Qualitative study (no intervention delivered)

Intervention type: OTHER
Intervention: Interviews/Focus groups/Participatory workshops
Description: Qualitative study (no intervention delivered)
Study: NCT05896917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Foot Orthosis
Description: 3D printed foot orthoses designed and fabricated at the Taibah University

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prefabricated Foot Orthosis
Description: Generic foot orthoses available commercially
Study: NCT04731675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMB-05X
Description: AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R
Study: NCT04876768

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of different concentrations of oxygen during ERCP
Description: The endoscopic intervention will be conducted in the endoscopy suite located at UK Albert B. Chandler Hospital in Lexington, Kentucky. ERCP/EUS uses an endoscope which is a long flexible narrow tube with a camera at the end is passed through the mouth, esophagus, stomach and the first part of the duodenum. The goal is to access a small elevation in the duodenum called the papilla of Vater. This papilla drains the biliary and pancreatic ducts which brings digestive juices from the liver, gallbladder and the pancreas. The endoscopist will inject contrast dye through the papilla into the ducts and takes X-rays to show lesions such as stones, strictures or blockages. If appropriate these can be treated by passing instruments through a port in the endoscope. Immediately following the endoscopic intervention; complications (bleeding, aspiration, perforation) will be recorded by study personnel as either yes or no, which will be used to assess the overall success of the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of different concentrations of oxygen during ERCP
Description: The endoscopic intervention will be conducted in the endoscopy suite located at UK Albert B. Chandler Hospital in Lexington, Kentucky. ERCP/EUS uses an endoscope which is a long flexible narrow tube with a camera at the end is passed through the mouth, esophagus, stomach and the first part of the duodenum. The goal is to access a small elevation in the duodenum called the papilla of Vater. This papilla drains the biliary and pancreatic ducts which brings digestive juices from the liver, gallbladder and the pancreas. The endoscopist will inject contrast dye through the papilla into the ducts and takes X-rays to show lesions such as stones, strictures or blockages. If appropriate these can be treated by passing instruments through a port in the endoscope. Immediately following the endoscopic intervention; complications (bleeding, aspiration, perforation) will be recorded by study personnel as either yes or no, which will be used to assess the overall success of the procedure.
Study: NCT05908578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Exercise Training
Description: Two sessions per week of high-intensity interval training (30 min each) and two sessions per week of continuous endurance exercise (30 min each). All exercise sessions will be performed on a stationary bike under supervision by an investigator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Frequency Exercise Training
Description: One session per week of high-intensity interval training (60 min) and one session per week of continuous endurance exercise (60 min). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
Study: NCT05245305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Program
Description: The intervention was structured as 11 weeks, taking into account the group. The program takes 2-2.5 hours per week. The program includes raisin exercise, body scanning meditation, breath awareness meditation, sitting meditation, mindfull movement, walking meditation, vision meditation, compassion meditation,mindfulness communication and day of silence.
Study: NCT05869110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of odours on calorie intake, food choice and metabolic parameters
Description: Evaluation of the effects of olfactory stimulation compared to placebo on calorie intake and preference of food during a test-buffet.~Odours will be assigned in a randomized order. Each participant will receive both odours, in between there will be a wash-out period of 1 week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Effects of odours on calorie intake, food choice and metabolic parameters
Description: Evaluation of the effects of olfactory stimulation compared to placebo on calorie intake and preference of food during a test-buffet.~Odours will be assigned in a randomized order. Each participant will receive both odours, in between there will be a wash-out period of 1 week.
Study: NCT04312945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
Study: NCT05076747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular training
Description: 8 weeks of cardiovascular training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: 8 weeks of Standard Therapy
Study: NCT05590117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline is a potent anti inflammatory may prevent chemotherapy induced neuropathy and mucositis and will be administered 400mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFOX-6 regimen
Description: 12 cycles of FOLFOX-6 regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX-6 regimen
Description: 12 cycles of FOLFOX-6 regimen
Study: NCT04785040

Intervention type: OTHER
Intervention: The groups evaluated by The Musculoskeletal Pain Intensity and Interference Questionnaire for Professional Orchestra Musicians, Brief Pain Inventory, QuickDASH and Fatigue Severity Scale
Description: The groups evaluated by The Musculoskeletal Pain Intensity and Interference Questionnaire for Professional Orchestra Musicians, Brief Pain Inventory, QuickDASH and Fatigue Severity Scale
Study: NCT06528509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-Generated Informative Videos
Description: Participants in the experimental arm will receive an AI-generated video designed to provide comprehensive information about cataract surgery. The video will cover key aspects of the procedure, including the nature of the surgery, potential risks, benefits, and postoperative care. The video will be produced in English for Cohort A, and translated into Bengali for Cohort B.~The video will be delivered to participants via a secure link sent to their mobile devices or email. Patients can watch the video at their convenience, and they are encouraged to view it as many times as necessary to fully understand the information provided. The video link will be provided once after the initial clinic appointment, but patients can access and watch the video multiple times.~The videos will be created using the Synthesia platform, which uses artificial intelligence to generate realistic, photo-realistic digital avatars that deliver the information in a personalized and engaging manner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Written Information Brochures
Description: Participants in the control arm will receive traditional written information brochures about cataract surgery. These brochures are designed to deliver detailed and essential information in a clear and understandable format. The brochures will be handed to participants during their face-to-face clinic appointment. Patients can read the material at their convenience and keep it for future reference. These brochures follow standardized guidelines and recommendations to ensure that all relevant information is included and presented in an accessible manner. The leaflet will be supplied in English for Cohort A, and Bengali for Cohort B.
Study: NCT05846217

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Multiwave Locked System
Description: Multiwave Locked System laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiwave Locked System
Description: Multiwave Locked System laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.
Study: NCT05587426

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SFF
Description: Ingestion of 20g of SFF after 10-14 hours of fasting

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Ingestion of 20g of glucose after 10-14 hours of fasting

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SFF chocolate chips
Description: Ingestion of 50g of chocolate chips made with SFF after 10-14 hours of fasting

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular chocolate chips
Description: Ingestion of 50g of regular chocolate chips after 10-14 hours of fasting
Study: NCT05922813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMI2004
Description: hyaluronidase, recombinant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: Normal Saline
Study: NCT05688254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOREST-A
Description: The internet-based psychosocial intervention will be delivered. The intervention comprises six modules: introduction, relaxation, psychological detachment, mastery, control, and summary, within psychoeducation and exercises in each module. The interactions with psychologists will be on demand. The whole intervention duration will be 4 weeks.
Study: NCT05221749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanosilver Fluoride (NSF)
Description: Optimized synthesis of Nanosilver Fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver diamine fluoride
Description: Silver Diamine Fluoride